Iris Navarro-Millán1, Mangala Rajan2, Geyanne E Lui2, Lisa M Kern2, Laura C Pinheiro2, Monika M Safford2, Sebastian E Sattui3, Jeffrey R Curtis4. 1. Weill Cornell Medicine, Division of General Internal Medicine, New York, NY, United States; Hospital for Special Surgery, Division of Rheumatology, New York, NY, United States. Electronic address: yin9003@med.cornell.edu. 2. Weill Cornell Medicine, Division of General Internal Medicine, New York, NY, United States. 3. Hospital for Special Surgery, Division of Rheumatology, New York, NY, United States. 4. University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, United States.
Abstract
OBJECTIVE: To determine racial/ethnic differences in the use of conventional synthetic or biologic disease-modifying anti-rheumatic drugs (csDMARDs or bDMARDs, respectively) and long-term glucocorticoids (GC) or opioids among beneficiaries of the Social Security Disability Insurance (SSDI) with rheumatoid arthritis (RA) and <65 years old. METHODS: Serial cross-sectional analyses of Centers for Medicare and Medicaid Services claims data (2007, 2011, and 2014) for individuals <65 years old with RA receiving SSDI Medicare and Medicaid, no longer working because they were considered disabled. Generalized estimating equation models were used to determine whether the proportion of patients who used csDMARD, bDMARD, long-term GC, and long-term opioids differed by race/ethnicity. RESULTS: There were 12,931; 15,033; and 15,599 participants in 2007, 2011, and 2014, respectively. The overall use of csDMARD without bDMARD among beneficiaries of the SSDI were 31.1%, 30.3%, and 29.2%; 50.2%, 51.7%, and 53.8% used bDMARDs; 37.6%, 36.1%, and 34.4% used long-term GC; and 61.1%, 63.8%, and 63.7% used long-term opioids in years 2007, 2011, and 2014 respectively. The use of csDMARDs without bDMARDs was higher and the use of bDMARDs was lower among Blacks compared to Whites (adjusted absolute difference: +3.0%, +5.0%, and +3.3% for csDMARDs without bDMARDs and -4.6%, -5.7%, and -4.0% for bDMARDs in 2007, 2011, and 2014, respectively; all p<0.05). The use of bDMARDs was higher among Hispanics compared to Whites (adjusted absolute difference: +7.1%, +7.3%, and +7.5% in 2007, 2011, and 2014, respectively; all p<0.05). Long-term GC use was lower among Hispanics than among Whites only in year 2014 (absolute percentage point difference of -4.2%); no other difference in long-term GC use was identified. Whites were the patients with the highest use of long-term opioids (more than two third in each calendar year). CONCLUSION: Racial and ethnic differences exists in regards to the treatment of RA among beneficiaries of the SSDI. These findings suggest that this already vulnerable population of patients with RA can also have a racial and ethnic disparity that can contribute to additional disease burden and that should be examined in order to inform future interventions or even inform future policy changes to the SSDI.
OBJECTIVE: To determine racial/ethnic differences in the use of conventional synthetic or biologic disease-modifying anti-rheumatic drugs (csDMARDs or bDMARDs, respectively) and long-term glucocorticoids (GC) or opioids among beneficiaries of the Social Security Disability Insurance (SSDI) with rheumatoid arthritis (RA) and <65 years old. METHODS: Serial cross-sectional analyses of Centers for Medicare and Medicaid Services claims data (2007, 2011, and 2014) for individuals <65 years old with RA receiving SSDI Medicare and Medicaid, no longer working because they were considered disabled. Generalized estimating equation models were used to determine whether the proportion of patients who used csDMARD, bDMARD, long-term GC, and long-term opioids differed by race/ethnicity. RESULTS: There were 12,931; 15,033; and 15,599 participants in 2007, 2011, and 2014, respectively. The overall use of csDMARD without bDMARD among beneficiaries of the SSDI were 31.1%, 30.3%, and 29.2%; 50.2%, 51.7%, and 53.8% used bDMARDs; 37.6%, 36.1%, and 34.4% used long-term GC; and 61.1%, 63.8%, and 63.7% used long-term opioids in years 2007, 2011, and 2014 respectively. The use of csDMARDs without bDMARDs was higher and the use of bDMARDs was lower among Blacks compared to Whites (adjusted absolute difference: +3.0%, +5.0%, and +3.3% for csDMARDs without bDMARDs and -4.6%, -5.7%, and -4.0% for bDMARDs in 2007, 2011, and 2014, respectively; all p<0.05). The use of bDMARDs was higher among Hispanics compared to Whites (adjusted absolute difference: +7.1%, +7.3%, and +7.5% in 2007, 2011, and 2014, respectively; all p<0.05). Long-term GC use was lower among Hispanics than among Whites only in year 2014 (absolute percentage point difference of -4.2%); no other difference in long-term GC use was identified. Whites were the patients with the highest use of long-term opioids (more than two third in each calendar year). CONCLUSION: Racial and ethnic differences exists in regards to the treatment of RA among beneficiaries of the SSDI. These findings suggest that this already vulnerable population of patients with RA can also have a racial and ethnic disparity that can contribute to additional disease burden and that should be examined in order to inform future interventions or even inform future policy changes to the SSDI.
Authors: Li-Hao Chu; Cecilia Portugal; Aniket A Kawatkar; William Stohl; Michael B Nichol Journal: Arthritis Care Res (Hoboken) Date: 2013-02 Impact factor: 4.794
Authors: Amy J H Kind; Steve Jencks; Jane Brock; Menggang Yu; Christie Bartels; William Ehlenbach; Caprice Greenberg; Maureen Smith Journal: Ann Intern Med Date: 2014-12-02 Impact factor: 25.391
Authors: Deborah A Levine; Cora E Lewis; O Dale Williams; Monika M Safford; Kiang Liu; David A Calhoun; Yongin Kim; David R Jacobs; Catarina I Kiefe Journal: Hypertension Date: 2010-12-06 Impact factor: 10.190
Authors: S Louis Bridges; Zenoria L Causey; Paula I Burgos; B Quynh N Huynh; Laura B Hughes; Maria I Danila; Amalia van Everdingen; Stephanie Ledbetter; Doyt L Conn; Ashutosh Tamhane; Andrew O Westfall; Beth L Jonas; Leigh F Callahan; Edwin A Smith; Richard Brasington; Larry W Moreland; Graciela S Alarcón; Désirée M van der Heijde Journal: Arthritis Care Res (Hoboken) Date: 2010-05 Impact factor: 4.794
Authors: Jeffrey R Curtis; Lang Chen; Leslie R Harrold; Pongthorn Narongroeknawin; George Reed; Daniel H Solomon Journal: Arthritis Care Res (Hoboken) Date: 2010-01-15 Impact factor: 4.794
Authors: Jeffrey D Greenberg; Tanya M Spruill; Ying Shan; George Reed; Joel M Kremer; Jeffrey Potter; Yusuf Yazici; Gbenga Ogedegbe; Leslie R Harrold Journal: Am J Med Date: 2013-12 Impact factor: 4.965
Authors: Seo Young Kim; Amber Servi; Jennifer M Polinski; Helen Mogun; Michael E Weinblatt; Jeffrey N Katz; Daniel H Solomon Journal: Arthritis Res Ther Date: 2011-02-23 Impact factor: 5.156
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: PLoS Med Date: 2007-10-16 Impact factor: 11.069
Authors: Troy B Amen; Tyler J Chavez; Edward Christopher Dee; Nathan H Varady; Jasper Seth Yao; Joseph Alexander Paguio; Antonia F Chen Journal: Clin Rheumatol Date: 2022-03-09 Impact factor: 2.980